A Phase 2 Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Sep 2017
At a glance
- Drugs Capmatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 22 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 17 May 2016 Status changed from not yet recruiting to recruiting.
- 03 May 2016 Planned initiation date changed from 1 Apr 2016 to 1 May 2016.